Zobrazeno 1 - 10
of 5 253
pro vyhledávání: '"TRAMETINIB"'
Autor:
Gal Rubinstein, Benjamin Izar, Diana E. McDonnell, Andrea Fernandez Valledor, Justin A. Fried, Kevin Clerkin, Edward F. Lin, Dor Lotan, Farhana Latif, Gabriel Sayer, Nir Uriel, Jayant K. Raikhelkar
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-4 (2024)
Abstract Background Cancer survivors (CS) comprise a particularly high-risk group for both de-novo and recurrent malignancies after solid organ transplantation. Case presentation We report a case of relapsed melanoma, presented as metastatic disease
Externí odkaz:
https://doaj.org/article/0d335aeb221c4937a728f4e1b0d66e9a
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Papillary craniopharyngiomas are rare tumors prevalent to the precision oncology world due to their high rate of BRAF V600E mutations. Symptoms include vision loss, neuroendocrine dysfunction, and cognitive dysfunction. Treatment involves an interdis
Externí odkaz:
https://doaj.org/article/b4a741bb71e247abb31e82558ed854ab
Autor:
Kensuke Namba, Kazutoshi Isobe, Hiroki Wakabayashi, Ryogo Ohashi, Hiromasa Sakurai, Daiki Sakai, Yusuke Irie, Kenta Takashima, Yu Murakami, Kaichi Kaneko, Nobuyuki Hiruta, Yasuo Matsuzawa
Publikováno v:
Respirology Case Reports, Vol 12, Iss 10, Pp n/a-n/a (2024)
Abstract BRAF is a mediator that activates the mitogen‐activated protein kinase pathway. A mutation in BRAF can cause abnormal pathway activation, leading to cell proliferation. In a Phase II study, the combination therapy of the BRAF inhibitor dab
Externí odkaz:
https://doaj.org/article/9dcef2518b7a436daccff34d260194dd
Autor:
Aram A. Musaelyan, Ekaterina M. Anokhina, Alina I. Turdubaeva, Natalia V. Mitiushkina, Anastasia N. Ershova, Anna D. Shestakova, Aigul R. Venina, Evgeny N. Imyanitov, Sergey V. Orlov
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 3, Pp 780-788 (2024)
Systemic chemotherapy is the main treatment option for patients with advanced intrahepatic cholangiocarcinoma (iCCA), however, its efficacy is limited. Herein, we report a young patient with NRAS-mutated chemoresistant metastatic iCCA, who received s
Externí odkaz:
https://doaj.org/article/15c6b988128b481890e948ca980a13a8
Autor:
Afrodité Németh, Gréta L. Bányai, Nikolett K. Dobos, Tamás Kós, Anikó Gaál, Zoltán Varga, Edit I. Buzás, Delaram Khamari, Magdolna Dank, István Takács, A. Marcell Szász, Tamás Garay
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Extracellular vesicles (EVs) constitute a vital component of intercellular communication, exerting significant influence on metastasis formation and drug resistance mechanisms. Malignant melanoma (MM) is one of the deadliest forms of skin ca
Externí odkaz:
https://doaj.org/article/82cfcaeb75a74849a5be0051bae737b3
Autor:
Emmanuel Seront, Antoine Froidure, Nicole Revencu, Valerie Dekeuleneer, Philippe Clapuyt, Dana Dumitriu, Miikka Vikkula, Laurence M. Boon
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-6 (2024)
Abstract Repurposing anticancer drugs to vascular malformations has significantly improved patient outcomes. Complex Lymphatic Anomalies (CLA) are part of the spectrum of lymphatic malformations (LMs) that share similar oncogenic mutations to cancer.
Externí odkaz:
https://doaj.org/article/27565a7accc341e589e0e8225fd143af
Autor:
Ander Puyalto, María Rodríguez-Remírez, Inés López, Irati Macaya, Elizabeth Guruceaga, María Olmedo, Anna Vilalta-Lacarra, Connor Welch, Sergio Sandiego, Silvestre Vicent, Karmele Valencia, Alfonso Calvo, Ruben Pio, Luis E. Raez, Christian Rolfo, Daniel Ajona, Ignacio Gil-Bazo
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-19 (2024)
Abstract Background The identification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This study analyzes the effects of trametinib on Id1 protein, a ke
Externí odkaz:
https://doaj.org/article/a7f566efdb754d68bd28062af5ab4148
Autor:
Ke Cheng, Zijian Zhou, Qiangxing Chen, Zixin Chen, Yu Cai, He Cai, Shangdi Wu, Pan Gao, Yunqiang Cai, Jin Zhou, Xin Wang, Zhong Wu, Bing Peng
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is not sensitive to most chemotherapy drugs, leading to poor chemotherapy efficacy. Recently, Trametinib and Palbociclib have promising prospects in the treatment of pancreatic cancer. This article aim
Externí odkaz:
https://doaj.org/article/677acbb956ea4a74afd45acba5093f15
Autor:
Takako Inoue, Kei Kunimasa, Motohiro Tamiya, Takahisa Kawamura, Toshiyuki Minami, Kazumi Nishino
Publikováno v:
Thoracic Cancer, Vol 15, Iss 11, Pp 929-933 (2024)
Abstract We present a patient with lung adenocarcinoma showing high PD‐L1 expression and BRAF V600E mutation, who achieved a remarkable long‐term response to the combination therapy of dabrafenib and trametinib (DT treatment) after disease progre
Externí odkaz:
https://doaj.org/article/8d66f6c5b4744281b900c0ad4f7f6b80
BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country
Autor:
Dima Abu Laban, Abeer Alsharif, Maysa Al-Hussaini, Mouness Obeidat, Bayan Maraqa, Qasem Alzoubi, Awni Musharbash, Saad Jaddoua, Raed Ramlawi, Kawther Khaleifeh, Ahmad Kh. Ibrahimi, Nasim Sarhan, Eric Bouffet, Nisreen Amayiri
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionMost pediatric low-grade-gliomas (LGG) and some high-grade-gliomas (HGG) have alterations in the RAS/MAPK pathway. Promising high tumor response rates were achieved using BRAF/MEK inhibitors, however data on their use in low-middle-income
Externí odkaz:
https://doaj.org/article/a23babfb377e407680f20d2e4d1da559